RACHEL REYES: Open Payments
NPI 1194298596 · SAN ANGELO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,005 in 41 payments from 7 companies in 2025. Trend: 2023 $1,958 · 2024 $2,876 · 2025 $1,005
Food & beverage: $1,005
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $495 |
| GlaxoSmithKline, LLC. | 14 | $234 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $77 |
| Verona Pharma, Inc. | 3 | $64 |
| GENZYME CORPORATION | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| Insmed, Inc. | 1 | $23 |
Products named: TEZSPIRE, TRELEGY ELLIPTA, DUPIXENT, AIRSUPRA, NUCALA, Ohtuvayre, OFEV, FASENRA.
Industry payments across TX — which companies pay providers there.
